黑料网

STOCK TITAN

Employers Enhanced Health Benefits in 2024, Adding Coverage for Weight-Loss Medications and IVF Despite Growing Health Costs, Mercer Survey Finds

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Positive)
Tags

Mercer's 2024 National Survey reveals employers are enhancing health benefits while managing rising costs. The average per-employee health insurance cost reached $16,501 in 2024, up 5% from 2023, with a projected 6% increase in 2025. Prescription drug costs rose 7.7% in 2024, driven by GLP-1 medications for diabetes and weight loss.

Notable trends include increased coverage for obesity medications (44% of large employers), IVF treatments (47% of large employers), and expanded medical plan choices. 65% of large employers now offer three or more healthcare options. Additionally, employers are focusing on cancer support, virtual primary care, and specialized health navigation services to improve care quality and accessibility.

Il sondaggio nazionale di Mercer del 2024 rivela che i datori di lavoro stanno migliorando i benefici sanitari, mentre gestiscono l'aumento dei costi. Il costo medio dell'assicurazione sanitaria per dipendente ha raggiunto $16,501 nel 2024, con un aumento del 5% rispetto al 2023, e una proiezione di aumento del 6% nel 2025. I costi dei farmaci prescritti sono aumentati del 7,7% nel 2024, spinti dai farmaci GLP-1 per il diabete e la perdita di peso.

Tendenze significative includono una maggiore copertura per i farmaci contro l'obesit脿 (44% dei grandi datori di lavoro), i trattamenti di IVF (47% dei grandi datori di lavoro) e una maggiore scelta nei piani medici. Il 65% dei grandi datori di lavoro ora offre tre o pi霉 opzioni sanitarie. Inoltre, i datori di lavoro si stanno concentrando sul supporto per il cancro, sull'assistenza primaria virtuale e sui servizi di navigazione sanitaria specializzati per migliorare la qualit脿 e l'accessibilit脿 delle cure.

La Encuesta Nacional de Mercer 2024 revela que los empleadores est谩n mejorando los beneficios de salud mientras gestionan el aumento de costos. El costo promedio del seguro de salud por empleado alcanz贸 $16,501 en 2024, un aumento del 5% con respecto a 2023, con un incremento proyectado del 6% para 2025. Los costos de medicamentos recetados aumentaron un 7.7% en 2024, impulsados por los medicamentos GLP-1 para la diabetes y la p茅rdida de peso.

Las tendencias notables incluyen un mayor cobertura para medicamentos contra la obesidad (44% de los grandes empleadores), tratamientos de IVF (47% de los grandes empleadores) y una mayor variedad en opciones de planes m茅dicos. El 65% de los grandes empleadores ahora ofrece tres o m谩s opciones de atenci贸n m茅dica. Adem谩s, los empleadores se est谩n enfocando en el apoyo al c谩ncer, atenci贸n primaria virtual y servicios de navegaci贸n de salud especializados para mejorar la calidad y accesibilidad de la atenci贸n.

毹胳劀鞚 2024雲 甑皜 臁办偓鞐 霐半ゴ氅, 瓿犾毄欤缄皜 牍勳毄 靸侅姽鞚 甏毽晿電 霃欖嫓鞐 瓯搓皶 順滍儩鞚 臧曧檾頃橁碃 鞛堨姷雼堧嫟. 歆侅洂 1鞚鸽嫻 韽夑窢 瓯搓皶 氤错棙 牍勳毄鞚 2024雲勳棎 $16,501鞐 霃勲嫭頄堨溂氅, 鞚措姅 2023雲 雽牍 5% 歃濌皜頃 靾橃箻搿 2025雲勳棎電 6% 歃濌皜頃 瓴冹溂搿 鞓堨儊霅╇媹雼. 觳橂癌鞎 牍勳毄鞚 2024雲勳棎 7.7% 歃濌皜頄堨溂氅, 鞚措姅 雼闺嚚氤 氚 觳挫 臧愲焿鞚 鞙勴暅 GLP-1 鞎诫鞐 鞚橅暣 齑夒皽霅橃棃鞀惦媹雼.

欤茧頃犽頃 瓴巾枼鞙茧電 牍勲 旃橂 鞎诫鞐 雽頃 氤挫灔 歃濌皜(雽攴滊 瓿犾毄欤检潣 44%), IVF 旃橂(雽攴滊 瓿犾毄欤检潣 47%), 攴鸽Μ瓿 頇曤寑霅 鞚橂 瓿勴殟 靹犿儩鞚 鞛堨姷雼堧嫟. 雽攴滊 瓿犾毄欤检潣 65%臧 鞚挫牅 靹 臧歆 鞚挫儊鞚 鞚橂 鞓奠厴鞚 鞝滉车頃╇媹雼. 於旉皜搿, 瓿犾毄欤茧摛鞚 鞎 歆鞗, 臧靸 1彀 歆勲 氚 鞝勲 瓯搓皶 韮愳儔 靹滊箘鞀るゼ 韱淀暣 旃橂鞚 歆堦臣 鞝戧芳靹膘潉 頄レ儊鞁滍偆電 雿 歆戩頃橁碃 鞛堨姷雼堧嫟.

Le sondage national de Mercer 2024 r茅v猫le que les employeurs am茅liorent les avantages en mati猫re de sant茅 tout en g茅rant l'augmentation des co没ts. Le co没t moyen de l'assurance maladie par employ茅 a atteint 16 501 $ en 2024, soit une augmentation de 5 % par rapport 脿 2023, avec une augmentation projet茅e de 6 % pour 2025. Les co没ts des m茅dicaments prescrits ont augment茅 de 7,7 % en 2024, tir茅s par les m茅dicaments GLP-1 pour le diab猫te et la perte de poids.

Les tendances notables incluent une couverture accrue pour les m茅dicaments contre l'ob茅sit茅 (44 % des grands employeurs), les traitements de FIV (47 % des grands employeurs) et une expansion des choix de plans m茅dicaux. 65 % des grands employeurs offrent d茅sormais trois options de soins de sant茅 ou plus. De plus, les employeurs se concentrent sur le soutien au cancer, les soins primaires virtuels et les services de navigation en sant茅 sp茅cialis茅s pour am茅liorer la qualit茅 et l'accessibilit茅 des soins.

Die nationale Umfrage von Mercer 2024 zeigt, dass die Arbeitgeber die Gesundheitsleistungen verbessern und gleichzeitig die steigenden Kosten managen. Die durchschnittlichen Gesundheitsversicherungs kosten pro Mitarbeiter beliefen sich im Jahr 2024 auf 16.501 $, was einem Anstieg von 5 % im Vergleich zu 2023 entspricht, mit einem prognostizierten Anstieg von 6 % im Jahr 2025. Die Kosten f眉r verschreibungspflichtige Medikamente stiegen im Jahr 2024 um 7,7 %, bedingt durch GLP-1-Medikamente gegen Diabetes und zur Gewichtsreduktion.

Bemerkenswerte Trends sind unter anderem eine erh枚hte Abdeckung von Medikationen gegen Fettleibigkeit (44 % der gro脽en Arbeitgeber), IVF-Behandlungen (47 % der gro脽en Arbeitgeber) und erweiterte Optionen bei den medizinischen Pl盲nen. 65 % der gro脽en Arbeitgeber bieten jetzt drei oder mehr Gesundheitsoptionen an. Zus盲tzlich konzentrieren sich die Arbeitgeber auf die Unterst眉tzung bei Krebs, virtuelle Prim盲rversorgung und spezialisierte Gesundheitsnavigation, um die Behandlungsqualit盲t und -zug盲nglichkeit zu verbessern.

Positive
  • None.
Negative
  • None.

NEW YORK--(BUSINESS WIRE)-- , a business of Marsh McLennan (NYSE: MMC) and a global leader in helping clients realize their investment objectives, shape the future of work and enhance health and retirement outcomes for their people, released results from its .

The survey found that the average per-employee cost of employer-sponsored health insurance reached $16,501 in 2024, an increase of about 5% year over year, with employers expecting an increase of about 6% in 2025.

鈥淓mployers doubled down on strategies to manage cost growth while finding ways to improve key benefits to support employees and their families in 2024, including expanded coverage for GLP-1 medications and fertility treatments,鈥 said Ed Lehman, Mercer鈥檚 US Health Leader.

The fastest-growing component of health benefit cost continues to be prescription drugs. Pharmacy benefit cost rose 7.7% in 2024, following an increase of 8.4% in 2023. One driver of this spend is the growing utilization of GLP-1 drugs for diabetes and weight loss.

While nearly all health plans cover GLP-1 drugs for diabetes, that is not the case for obesity treatment. However, in 2024, coverage for obesity drugs rose to 44% of all large employers (those with 500 or more employees), up from 41% last year. Of the largest employers (20,000 or more employees), 64% now offer coverage, up sharply from 56% in 2023.

鈥淕LP-1 medications may turn the tide on the obesity epidemic and positively impact downstream medical costs,鈥 said Tracy Watts, Mercer鈥檚 National Leader for US Health Policy. 鈥淐ost is clearly a concern, and employers are adding authorization requirements to ensure the medications are used by members who will benefit the most.鈥

Employers are also managing the rising cost of specialty drugs, including expensive gene and cell therapies for conditions such as hemophilia and sickle cell disease. The most common strategy to curb costs is working with medical carriers and pharmacy benefit managers to implement clinical management programs for patients.

Addressing affordability with more medical plan choices

Concerns about affordability have led employers to add medical plan choices that accommodate different financial and medical needs. This year, 65% of large employers offered three or more choices to employees, up from 60% in 2023, with the largest employers providing an average of five options.

One lower-cost option is an Exclusive Provider Organization (EPO) plan, which uses a closed provider network to help keep cost down. In 2024, 12% of all large employers and 29% of the largest employers offered an EPO option. Notably, about a third of these plans do not require a deductible, which is rare among Preferred Provider Organization (PPO) plans and not permitted for Health Savings Account (HSA) eligible plans. Currently, 5% of all covered US employees are enrolled in an EPO.

Promoting higher quality care

Many of the EPO plans offered by the largest employers (40%) incorporate a high-performance provider network, in which providers are selected based on quality and cost metrics, as do 10% of the PPO plans. 鈥淏y steering employees to providers of demonstrated quality and cost efficiency, better outcomes and cost savings result, a win for both employees and the plan sponsor,鈥 said Ms. Watts.

Another way to guide employees to higher quality, cost-efficient care is by providing specialized health navigation or advocacy services. Nearly half of all large employers (49%) have contracted a specialized vendor or purchased enhanced services from their health plan to provide assistance beyond standard customer service.

Family-forming benefits

Coverage for fertility treatment is becoming increasingly common, with in vitro fertilization (IVF) now covered by 47% of all large employers, up from 45% last year. Of the largest employers, 70% cover IVF, up from 62%. Elective egg freezing and elective sperm freezing are covered by 21% and 20% of all large employers, respectively.

Most large employers offering fertility benefits (64%) say that they are intended to be inclusive, meaning eligibility is not limited to those meeting the clinical definition of infertile. 鈥淔ertility benefits have become table stakes for employers wanting to offer comprehensive, inclusive benefits,鈥 added Ms. Watts.

Cancer support and other benefit enhancements

Employers are increasingly providing specialized support to employees dealing with cancer, including prevention and early detection campaigns, Centers of Excellence, case management, caregiver resources and workplace support. Two-thirds of large employers now provide at least one of these resources, with 20% of the largest employers having a robust cancer strategy and another 24% actively developing one.

Virtual primary care, offering convenient, low-cost access to physicians via text messaging, is a popular benefit that can enhance healthcare accessibility. In 2024, 20% of all large employers and 27% of the largest employers provided this service.

About Mercer鈥檚 National Survey of Employer-Sponsored Health Plans

Now in its 39th year, Mercer鈥檚 National Survey of Employer-Sponsored Health Plans included 2,194 employers in 2024. Results are weighted to represent all US health plan sponsors with 50 or more employees. Results are examined separately for employers with 500 or more employees (鈥渓arge鈥 employers) and those with 20,000 or more employees (鈥渓argest鈥 employers). The survey was fielded from June 12 through August 16, 2024.

About Mercer

, a business of (NYSE: MMC), is a global leader in helping clients realize their investment objectives, shape the future of work and enhance health and retirement outcomes for their people. Marsh McLennan is a global leader in risk, strategy and people, advising clients in 130 countries across four businesses: , , and . With annual revenue of $23 billion and more than 85,000 colleagues, Marsh McLennan helps build the confidence to thrive through the power of perspective. For more information, visit , or follow on and .

Media:

Ashleigh Jang

Mercer

+1 212-345-3965

Ashleigh.Jang@mercer.com

Source: Mercer

FAQ

What was the average cost of employer-sponsored health insurance in 2024 according to Mercer (MMC)?

According to Mercer's survey, the average per-employee cost of employer-sponsored health insurance reached $16,501 in 2024, representing a 5% increase from the previous year.

How many large employers covered GLP-1 drugs for obesity treatment in 2024?

In 2024, 44% of large employers (500+ employees) covered GLP-1 drugs for obesity treatment, up from 41% in 2023. Among the largest employers (20,000+ employees), coverage increased to 64% from 56%.

What percentage of large employers offered IVF coverage in 2024?

According to Mercer's survey, 47% of large employers covered IVF treatments in 2024, up from 45% in 2023. Among the largest employers, 70% offered IVF coverage.

How much did pharmacy benefit costs increase in 2024?

Pharmacy benefit costs increased by 7.7% in 2024, following an 8.4% increase in 2023, making it the fastest-growing component of health benefit costs.

Marsh & McLennan Companies, Inc.

NYSE:MMC

MMC Rankings

MMC Latest News

MMC Stock Data

103.80B
490.60M
0.1%
90.7%
0.76%
Insurance Brokers
Insurance Agents, Brokers & Service
United States of America
NEW YORK